Nina Roy‐Kluth
A5092623504- Dementia and Cognitive Impairment Research
- Functional Brain Connectivity Studies
- Alzheimer's disease research and treatments
- Cerebrospinal fluid and hydrocephalus
- Neurological Disease Mechanisms and Treatments
- Memory and Neural Mechanisms
- Fetal and Pediatric Neurological Disorders
- Spinal Dysraphism and Malformations
- Health, Environment, Cognitive Aging
- Neural dynamics and brain function
- Craniofacial Disorders and Treatments
- Cognitive Abilities and Testing
- Advanced Neuroimaging Techniques and Applications
- Cholinesterase and Neurodegenerative Diseases
- Neuroscience and Music Perception
- Neurological and metabolic disorders
- Brain Tumor Detection and Classification
- Traumatic Brain Injury and Neurovascular Disturbances
- Neurological Disorders and Treatments
German Center for Neurodegenerative Diseases
2023-2025
Charité - Universitätsmedizin Berlin
2024
Humboldt-Universität zu Berlin
2024
Freie Universität Berlin
2024
University of Bonn
2023
Soluble amyloid beta (Aβ) oligomers have been suggested as initiating Aβ related neuropathologic change in Alzheimer's disease (AD) but their quantitative distribution and chronological sequence within the AD continuum remain unclear.
Abstract Single-value scores reflecting the deviation from (FADE score) or similarity with (SAME prototypical novelty-related and memory-related functional MRI activation patterns in young adults have been proposed as imaging biomarkers of healthy neurocognitive ageing. Here, we tested utility these potential diagnostic prognostic markers Alzheimer’s disease (AD) risk states like mild cognitive impairment (MCI) subjective decline (SCD). To this end, analysed subsequent memory data...
Abstract INTRODUCTION Subjective cognitive decline (SCD) in amyloid‐positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies. METHODS Eight hundred twenty‐one participants from SILCODE DELCODE cohorts, including normal controls (NC) with SCD recruited community or memory clinics, underwent neuropsychological assessments over up to 6 years....
Abstract INTRODUCTION Blood‐based biomarkers are a cost‐effective and minimally invasive method for diagnosing the early preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation‐immunoassay (IP‐IA) as test predicting cognitive decline. METHODS We measured levels beta (Aβ)X‐40 AβX‐42 in immunoprecipitated eluates from DELCODE cohort. Receiver‐operating characteristic (ROC) curves, regression analyses, Cox proportional hazard models were...
Abstract INTRODUCTION The beneficial effects of amyloid beta 1‐38, or Aβ(1‐38), on Alzheimer's disease (AD) progression in humans vivo remain controversial. We investigated AD patients' cerebrospinal fluid (CSF) Aβ(1‐38) and progression. METHODS Cognitive function diagnostic change were assessed annually for 3 years 177 Aβ‐positive participants with subjective cognitive decline (SCD), mild impairment (MCI), dementia from the German Center Neurodegenerative Diseases (DZNE) longitudinal study...
To determine the relevance of minor neuropsychological deficits (MNPD) in patients with subjective cognitive decline (SCD) regard to CSF levels Alzheimer disease (AD) biomarkers, decline, and clinical progression mild impairment (MCI).This study included SCD SCD-free, healthy control (HC) participants available baseline and/or longitudinal data from observational DZNE Longitudinal Cognitive Impairment Dementia study. We defined MNPD as a performance at least 0.5SD below mean on...
Participation in multimodal leisure activities, such as playing a musical instrument, may be protective against brain aging and dementia older adults (OA). Potential neuroprotective correlates underlying activity remain unclear.
Inferior frontal sulcal hyperintensities (IFSHs) on fluid-attenuated inversion recovery (FLAIR) sequences have been proposed to be indicative of glymphatic dysfunction. Replication studies in large and diverse samples are nonetheless needed confirm them as an imaging biomarker. We investigated whether IFSHs were tied Alzheimer's disease (AD) pathology cognitive performance. used data from 361 participants along the AD continuum, who enrolled multicentre DELCODE study. The rated visually...
Abstract Background Perivascular space (PVS) enlargement in ageing and Alzheimer’s disease (AD) the drivers of such a structural change humans require longitudinal investigation. Elucidating effects demographic factors, hypertension, cerebrovascular dysfunction, AD pathology on PVS dynamics could inform role brain health function as well complex pathophysiology AD. Methods We studied centrum semiovale (CSO) basal ganglia (BG) computationally over three to four annual visits 503 participants...
Abstract In functional magnetic resonance imaging (fMRI) studies, episodic memory is commonly investigated with the subsequent paradigm in which brain activity recorded during encoding and analyzed as a function of remembering forgetting. Impaired common individuals or at risk for Alzheimer’s disease (AD), but only few studies have reported effects AD its states like mild cognitive impairment (MCI). One reason this might be that responses may blunted MCI thus less likely to manifest fMRI...
Abstract Research on the impairment of episodic memory in Alzheimer’s disease often focuses processes rather than content specific images being remembered. We recently showed that patients with mild cognitive (MCI), Stage 3 disease, can memorize certain quite well, suggesting is not uniformly impaired. Certain images, other hand, could be memorized by MCI and were instead diagnostic for distinguishing from healthy older adults. In this study, we investigate whether poor related to impaired...
CSF biomarkers have immense diagnostic and prognostic potential for Alzheimer disease (AD). However, AD is still diagnosed relatively late in the process, sometimes even years after initial manifestation of cognitive symptoms. Thus, further identification required to detect related pathology preclinical stage predict decline. Our study aimed assess association neurogranin β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with decline individuals subjective (SCD).
Abstract Neurotransmitter systems of noradrenaline, dopamine, serotonin and acetylcholine are implicated in cognitive functions such as memory, learning attention known to be altered neurodegenerative diseases like Alzheimer’s disease. Specific brain structures involved these systems, e.g. the locus coeruleus, main source noradrenaline cortex, fact affected earliest by disease tau pathology. Preserved volumetric neurotransmitter specific areas could therefore an important neural resource for...
The NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective decline (SCD) and mild neurobehavioral symptoms (NPS).
Individuals with Alzheimer′s disease dementia postmortem show pathology in and heterogeneous degeneration of the Substantia Nigra (SN). However, it is unclear how SN related to cognitive dysfunction across continuum. In this study, using data from a prospective study (DELCODE), we investigated if in-vivo MRI measures are lower cases clinically defined than healthy control subjects (HC) they associated functional activity during processing novel visual stimuli subsequent recognition memory....
Abstract Background Differences in task‐fMRI activation have recently been found to be related neuropathological hallmarks of AD. However, the evolution fMRI‐based throughout AD disease progression and its relationship with other biomarkers remains elusive. Applying a model (DPM) multicentric cohort up four annual visits, we hope provide deeper insight into these relationships. Method We estimated stages using multivariate Gaussian Process (GP) DPM including CSF‐Aβ42/40 ratio, CSF‐p‐tau 181...
Abstract Background Differences in task‐fMRI activation have recently been found to be related neuropathological hallmarks of AD. However, the evolution fMRI‐based throughout AD disease progression and its relationship with other biomarkers remains elusive. Applying a model (DPM) multicentric cohort up four annual visits, we hope provide deeper insight into these relationships. Method We estimated stages using multivariate Gaussian Process (GP) DPM including CSF‐Aß42/40 ratio, CSF‐p‐tau181,...
Abstract In functional magnetic resonance imaging (fMRI) studies, episodic memory is commonly investigated with the subsequent paradigm in which brain activity recorded during encoding and analyzed as a function of remembering forgetting. Impaired common individuals or at risk for Alzheimer’s disease (AD), but only few studies have reported effects AD its states like mild cognitive impairment (MCI). One reason this might be that responses may blunted MCI thus less likely to manifest fMRI...
<title>Abstract</title> <bold>Background</bold>: The NIA-AA Research Framework on Alzheimer’s Disease (AD) proposes a transitional stage (stage 2) between the fully asymptomatic 1 and mild cognitive impairment 3) in evolution of symptoms over disease course. Proposed features 2 include subtle dysfunction, subjective decline (SCD) neurobehavioral symptoms. Here, we aimed to identify specific clusters participants based these assess association with amyloid positivity cognitively unimpaired...
Abstract Background Perivascular space (PVS) enlargement in ageing and Alzheimer’s disease (AD) its exacerbators require further investigation. Methods We studied centrum semiovale (CSO) basal ganglia (BG) PVS computationally over three to four annual visits 557 participants of the DZNE multicentre DELCODE cohort. tested volumetric changes relation ageing, sex, years education, hypertension, AD diagnosis, cerebrospinal-fluid-derived Amyloid Tau positivity interleukin 6 (IL-6). Results...
Abstract Single-value scores reflecting the deviation from (FADE score) or similarity with (SAME prototypical novelty-related and memory-related functional magnetic resonance imaging (fMRI) activation patterns in young adults have been proposed as biomarkers of healthy neurocognitive aging. Here, we tested utility these potential diagnostic prognostic markers Alzheimer’s disease (AD) risk states like mild cognitive impairment (MCI) subjective decline (SCD). To this end, analyzed subsequent...